Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.61 |
| ▸ | THRA | P10827 | 9/20 | 0.61 |
| ▸ | PPARG | P37231 | 6/20 | 0.61 |
| ▸ | RXRA | P19793 | 3/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.61 |
| ▸ | ITGAV | P06756 | 3/20 | 0.61 |
| ▸ | PCNA | P12004 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12837225 | 0.93 | THRB (0.56) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1525949 | 0.88 | MGLL (0.46) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL19309251 | 0.86 | THRB (0.43) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1525943 | 0.82 | EPHX2 (0.42) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL14239796 | 0.82 | MGLL (0.43) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1525910 | 0.81 | THRB (0.43) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL2829165 | 0.80 | ALDH1A1 (0.41) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL16155956 | 0.79 | THRB (0.68) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1525951 | 0.79 | THRB (0.40) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL19696744 | 0.79 | THRB (0.76) | THRBTHRAPPARGRXRAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9839614-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160199309-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS, LLC | 2016-07-14 | — | — | US | disclosed |
| US-9220788-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220788-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-8802240-B2 | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells | NANOPHARMACEUTICALS LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | NANOPHARMACEUTICALS LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2442800-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | Ordway Research Institute, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148007-A9 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC | 2011-03-03 | — | — | US | disclosed |
| WO-2010148007-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | ORDWAY RESEARCH INSTITUTE, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199309-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885PPARG 145/4885 |
| US-20120315320-A1 | USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS | TSHR, TPO, THRA | THRB 5/4885THRA 3/4885PPARG 317/4885 |
| US-20110052715-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | TSHR, THRA, TRHR | THRB 4/4885THRA 2/4885PPARG 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.